Search results for "intraductal"

showing 10 items of 23 documents

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal pap…

2017

Lesions affecting anogenital mammary-like glands (AGMLG) are histopathologically very similar to those seen in the breast but whether this morphological similarity is also reflected at the genetic level is unknown. To compare the underlying molecular mechanisms in lesions of AGMLG and their mammary counterparts, we analyzed the mutational profile of 16 anogenital neoplasms including 5 hidradenomas papilliferum (HP), 1 lesion with features of HP and fibroadenoma (FA), 7 FA, 3 phyllodes tumors (PhT)) and 18 analogous breast lesions (6 intraductal papillomas (IDP), 9 FA, and 3 PhT) by high-coverage next generation sequencing (NGS) using a panel comprising 50 cancer-related genes. Additionally,…

0301 basic medicinePathologymedicine.medical_specialtyHidradenomaClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsBiologyPathology and Forensic MedicineVulvaMED12Papilloma IntraductalLesionPhosphatidylinositol 3-Kinases03 medical and health sciencessymbols.namesake0302 clinical medicinePhyllodes TumorIntraductal papillomamedicineHumansBreastAgedSanger sequencingVulvar NeoplasmsHigh-Throughput Nucleotide SequencingPhyllodes tumorGeneral MedicineMiddle Agedmedicine.diseaseFibroadenomaTubular Sweat Gland Adenomas030104 developmental biologymedicine.anatomical_structureFibroadenoma030220 oncology & carcinogenesisMutationsymbolsFemalemedicine.symptomAnnals of Diagnostic Pathology
researchProduct

Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma

1993

Twenty-two women affected by metastatic breast carcinoma have been treated with a combination of levo folinic acid 100 mg/m 2 plus 5-fluorouracil 450 mg/m 2 i.v. on day 1-2, and epidoxorubicin 75-90 mg/m 2 on day 2. This treatment cycle was repeated every 21-28 days. No patients had previously received chemotherapy for metastatic disease. Fourteen patients (64%) showed a major objective response with 3 complete (14%) and 11 partial responses (50%). Three patients showed a stabilization of disease and 5 (23%) progressed. All patients received ondansetron as antiemetic treatment which led to complete protection from vomiting in 68% of cases. Grade 1-2 diarrhea was recorded in 27% of the patie…

AdultCancer Research5-flurouracilDose-Response Relationship DrugLevo folinic acidCarcinomaLeucovorinBreast NeoplasmsMiddle AgedBreast cancerCarcinoma Intraductal NoninfiltratingOncologyEpidoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFluorouracilAgedEpirubicin
researchProduct

Correlation of an estrogen receptor-related phosphoprotein with histopathological features in breast cancer.

1989

A series of 65 cases of different histological types of breast carcinoma was investigated for the immunohistochemical location of the estrogen receptor-related, 29 kD phosphoprotein using the ER-D5 monoclonal antibody.The ER-D5 response is heterogeneous in relation to some therapeutic limitations and is correlated with histopathological features of the tumors and survival. The main parameters for evaluation of breast cancers are reviewed, both those that are statistically correlated and those that are not apparently always correlated but are known to have considerable biological meaning, such as the ER-status of tumors.

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.drug_classClinical BiochemistryEstrogen receptorBreast NeoplasmsAdenocarcinomaMonoclonal antibodyPathology and Forensic MedicineCorrelationBreast cancermedicineBiomarkers TumorHumansNeoplasm InvasivenessAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseasePhosphoproteinsAdenocarcinoma MucinousCarcinoma PapillaryCarcinoma Intraductal NoninfiltratingOncologyReceptors EstrogenEstrogenPhosphoproteinImmunohistochemistrybusinessBreast carcinomaThe International journal of biological markers
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours an…

1985

Histology and fine structure of pancreatic ductal adenocarcinomas were assessed with respect to their significance for tumour growth and prognosis. The histological parameters included glandular differentiation, nuclear anaplasia, nuclear size, and mitotic activity (number of mitoses per high power field). Using these criteria three grades of malignancy were distinguished. They correlated well with the growth kinetics of seven human pancreatic ductal adenocarcinomas transplanted into nude mice. The tumour doubling time of a G 3 carcinoma was about half that of a G 1 carcinoma. On electron microscopy the tumour grade was reflected in the degree of functional differentiation of the neoplastic…

AdultMaleAgingPathologymedicine.medical_specialtyTime FactorsHistologyMice Inbred StrainsBiologyMalignancyPathology and Forensic MedicineMiceSex FactorsmedicineCarcinomaAnimalsHumansDoubling timePostoperative PeriodGrading (tumors)AnaplasiaAgedNeoplasm StagingHigh-power fieldCell NucleusHistologyGeneral MedicineMiddle AgedPrognosismedicine.diseasePancreatic NeoplasmsKineticsCarcinoma Intraductal Noninfiltratingmedicine.anatomical_structureFemalemedicine.symptomPancreasCell DivisionNeoplasm TransplantationHistopathology
researchProduct

Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis

2009

Aim To retrospectively establish the most frequently encountered diagnoses in patients with pancreatic calcifications and to investigate whether the association of certain findings could be helpful for diagnosis. Materials and methods One hundred and three patients were included in the study. The location and distribution of calcifications; presence, nature, and enhancement pattern of pancreatic lesions; pancreatic atrophy and ductal dilatation were recorded. Differences between patients with chronic pancreatitis and patients with other entities were compared by using Fisher's exact test. Results Patients had chronic pancreatitis ( n =70), neuroendocrine tumours ( n =14), intraductal papill…

AdultMalemedicine.medical_specialtyPancreatic diseaseSensitivity and SpecificityGastroenterologyCalcinosisPancreatitis ChronicInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingPancreatitis chronicPancreatic calcificationAgedRetrospective StudiesAged 80 and overIntraductal papillary mucinous neoplasmbusiness.industryPancreatic DuctsCalcinosisPancreatic DiseasesGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structurePancreatitisAdenocarcinomaFemaleRadiologyTomography X-Ray ComputedbusinessPancreasClinical Radiology
researchProduct

Autoantibodies in breast cancer: their use as an aid to early diagnosis

2007

There is increasing evidence that the immune system produces a humoral response to cancer-derived antigens. This study assessed the diagnostic potential of autoantibodies to multiple known tumour-associated proteins.Sera from normal controls (n = 94), primary breast cancer patients (n = 97) and patients with ductal carcinoma in situ (DCIS) (n = 40) were investigated for the presence of autoantibodies to p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2 and MUC1 antigens by enzyme-linked immunosorbent assay.Reproducibly elevated levels of autoantibodies were seen in at least one of the six antigens in 64% of primary breast cancer patient sera and 45% of patients with DCIS at a specificity of 85%. No …

AdultOncologyPathologymedicine.medical_specialtyAntibodies NeoplasmBreast NeoplasmsEnzyme-Linked Immunosorbent Assaymedicine.disease_causeSensitivity and SpecificityAutoimmunityCohort StudiesBreast cancerAntigenAntigens NeoplasmInternal medicinemedicineHumansMammographyNeoplasm Metastasisskin and connective tissue diseasesLymph nodeAgedAutoantibodiesAged 80 and overmedicine.diagnostic_testbusiness.industryAutoantibodyReproducibility of ResultsCancerHematologyMiddle Agedmedicine.diseaseCarcinoma LobularCarcinoma Intraductal NoninfiltratingEarly Diagnosismedicine.anatomical_structureIncreased riskReceptors EstrogenOncologyCase-Control StudiesFemalebusinessAnnals of Oncology
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

Imunohistochemical Demonstration of Carcinoembryonic Antigen (CEA) in 120 Mammary Carcinomas and its Correlation with Tumor Type, Grading, Staging Pl…

1985

Antisera to CEA were used for the immunohistochemical localization and quantification of this antigen in 120 Bouin-fixed, paraffin embedded mammary carcinomas. These results were compared to tumor type, grading, staging, biochemical receptor status, cytosolic CEA-levels of the same tumors, and preoperative plasma CEA-levels. Mammary carcinomas were usually characterized by a low percentage of CEA-positive tumor cells: 50.9% of the cases contained more than 5% CEA-positive tumor cells and were therefore defined as being CEA-histopositive in this study. A relation could be shown between CEA-histopositivity and the histologic tumor type. The majority of invasive lobular carcinomas, tubular, an…

AdultPathologymedicine.medical_specialtyReceptor Statusendocrine system diseasesBreast NeoplasmsPathology and Forensic MedicineImmunoenzyme TechniquesCarcinoembryonic antigenAntigenAntigens NeoplasmmedicineCarcinomaHumansneoplasmsEstrogen Receptor StatusGrading (tumors)Agedbiologybusiness.industryCarcinomaCell BiologyMiddle Agedmedicine.diseasedigestive system diseasesCarcinoembryonic AntigenCarcinoma Intraductal NoninfiltratingReceptors EstrogenInvasive lobular carcinomabiology.proteinImmunohistochemistryFemalebusinessPathology - Research and Practice
researchProduct